The leading market experts have placed a mean price target of $137.83 on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock. This price level, which is estimated to be attained in one-year indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $0.91 a share for the upcoming quarter and $3.30 for the current fiscal. Technical View The technical analysis of Ligand Pharmaceuticals Incorpor plainly substantiates that the 50-day moving average of Ligand Pharmaceuticals Incorpor is $117.35, and stock is hovering 4.77 or +4.06% distant from $117.35. It is noted that the 200-day MA is $108.57, and Ligand Pharmaceuticals Incorpor stock is $13.55 or +12.48% off from this point. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) 52-week high is $131.84 and the 52-week low is $71.63. This explains if the stock moves $-9.72, it will post a 52-week high. In event of $+70.49% points decline, a 52-week low will be hit. Taking the Valuation Aspect To emphasize the valuation of Ligand Pharmaceuticals Incorpor, shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ratio came in at 10.05. The stock last ended the trading session at $122.12 and registered a market cap of $2.54B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PEG ratio is at 0.81.
1 Chart Pattern Every Investor Should Know